CAMBRIDGE, Mass. - NeuroSense Therapeutics Ltd. (Nasdaq: NRSN), a biotech firm focusing on neurodegenerative disease treatments, has announced its return to compliance with Nasdaq's minimum bid price rule. The company's ordinary shares maintained a closing bid price of at least $1.00 over 10 consecutive business days, concluding on Monday, as required by Nasdaq Listing Rule 5550(a)(2) for continued listing on the exchange.
The Nasdaq Listing Qualifications Staff has acknowledged the resolution of the previous bid price deficiency. This development follows NeuroSense's recent announcement of positive results from the Phase 2b PARADIGM trial of its drug candidate PrimeC. CEO Alon Ben-Noon remarked that regaining compliance was a significant milestone in the company's progress.
NeuroSense is engaged in the clinical-stage development of therapies for serious neurodegenerative conditions such as ALS, Alzheimer's, and Parkinson's disease. The company adopts a multi-targeted therapeutic approach, aiming to address the complex nature of these illnesses. Results from a collaborative study with Biogen (NASDAQ:BIIB), assessing PrimeC's impact on neurofilament levels in PARADIGM participants, are expected to be reported soon.
This news piece is based on a press release statement from NeuroSense Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.